1350 - Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)

Page last updated: 05 November 2014

Application Detail

Status

Closed

Description of Medical Service

This service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion.

Description of Medical Condition

RVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

-

ESC

-

MSAC

-